Vasopharm raises €20m from Entrepreneurs Fund et al.
German biopharmaceutical company Vasopharm has raised €20m from Entrepreneurs Fund and other investors.
Heidelberg Capital Private Equity, UK-based Fort Rock Capital, Bayern Kapital and Hanseatic Asset Management also participated in the round.
The developer will use the fresh capital for the European phase-III study of its lead product VAS 203, which will be used to treat severe traumatic brain injuries. The drug developer finished the clinical trials and expects to treat its first patient in H1 2016.
British VC Entrepreneurs Fund is focused on western European life sciences and technology startups, typically investing €1-2m at the start and up to €5m over the lifespan of an investment.
Previous funding
In May 2009, EMBL Ventures led a €4.5m series-D round in Vasopharm, with HeidelbergCapital, Entrepreneurs Fund and KfW participating. The series-D enabled the company to proceed with phase-IIa clinical trials for its therapeutic compound VAS 203.
In August 2001, Vasopharm received €6.5m from 3i, Future Capital and TBG; in January 2006 it raised €10m from 3i and Entrepreneurs Fund; and in February 2008 it received €3m from Heidelberg Capital, Entrepreneurs Fund and KfW.
HeidelbergCapital became a backer of Vasopharm at the end of 2007, when 3i sold 23 minority stakes in German firms to the secondaries direct specialist.
Company
Vasopharm was founded as a spin-off from the University of Würzburg medical school in July 1998. Employing a staff of 20, the pharmaceutical company is dedicated to the discovery and development of therapeutics for the treatment of cerebro- and cardio-vascular diseases and their consequences.
Vasopharm stated the combined US and European markets for an effective medication for the treatment of cranio-cerebral trauma exceeds $1bn.
People
Vasopharm – Christian Wandersee (CEO).
Fort Rock Capital – Mario Alberto Accardi (venture partner).
Advisers
Company – P+P Pöllath + Partners (Legal).
Equit (Entrepreneurs Fund, Hanseatic Asset Management LBG) – Jones Day (Legal).
Equity (Fort Rock) – Hogan Lovells (Legal).
Equity (Bayern Capital) – Weitnauer Rechtsanwaelte (Legal).
More on Early-stage
Sidekick spinoffs: Insurtech scale-ups attract PE interest
Investment set to break EUR 1.1bn mark this year as sponsors seek for rising stars
World Fund leads EUR 128m raise for quantum computing group IQM
Series-A2 for Finnish startup focused on combating the climate crisis also backed by the EIB
Gorillas raises circa USD 1bn in Delivery Hero-led Series C
New funding comes just seven months after a Series B, with the company doubling in value
French mega-rounds shoot up in 2021
France has already seen as many rounds of EUR 100m and above than in 2019 and 2020 combined, Unquote Data shows
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater